Mitsubishi Tanabe Pharma Corp. Newsletter
-
Akebia joins GSK in US market for oral CKD anaemia drugs
28 Mar 2024 17:12 GMT
… GSK’s Jesduvroq.
Akebia’s drug, which like Jesduvroq (daprodustat … data potentially linking the drug to clotting complications and …
The company partners the drug with Medice Arzneimittel Pütter … and is sold by Mitsubishi Tanabe.
Akebia’s president and …
-
Efficacy of HP-3070, A Once-Daily Asenapine Transdermal System, in the Treatment of Adults with Schizophrenia: A PANSS Five-Factor Analysis
29 Mar 2024 14:20 GMT
… extrapyramidal symptoms such as drug-induced parkinsonism or dystonia, … MapLight, Marvin, MedAvante-ProPhase, Merck, Mitsubishi-Tanabe, Neumora, Neurocrine, Neurelis, Noema, … #47;JCP.18nr12554
8. Hisamitsu Pharmaceutical Co., Inc. SECUADO® (asenapine) …
-
Mitsubishi Tanabe Pharma America Announces Publication of Positive Results from Phase 3 BouNDless Trial of Investigational ND0612 in People with Parkinson's Disease Experiencing Motor Fluctuations
18 Mar 2024 14:35 GMT
… and LinkedIn.
About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi … ;precision medicine" to provide drugs with high treatment satisfaction and …
-
Mitsubishi Tanabe Pharma & Daiichi Sankyo announce expiration of MAA for Tenelia tablets, Tenelia OD tablets and Canaglu tablets
05 Mar 2024 07:16 GMT
… are currently jointly conducted with Mitsubishi Tanabe Pharma.
Mitsubishi Tanabe Pharma and Daiichi Sankyo will cooperate … of ethical drugs and prompt and appropriate information provision activities, Mitsubishi Tanabe Pharma and …
-
Mitsubishi Tanabe Pharma America Announces Presentations in Parkinson's Disease at 2024 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD)
04 Mar 2024 18:06 GMT
… and LinkedIn.
About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi … ;precision medicine" to provide drugs with high treatment satisfaction and …
-
Mitsubishi Tanabe Pharma America to Showcase Presentations on ALS Research at 2024 MDA Clinical & Scientific Conference
01 Mar 2024 17:31 GMT
… )
The U.S. Food and Drug Administration (FDA) approved RADICAVA® … followed by a two-week drug-free period. All cycles thereafter … LinkedIn.
About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi …
-
Akebia's Vafseo finally gets its shot at US chronic kidney disease market after FDA approval
28 Mar 2024 22:13 GMT
… data from Japan, where Mitsubishi Tanabe Pharma is handling commercialization of … any severe instances of drug-induced liver injury, bolstering … agents, Butler explained. The drug, a hypoxia-inducible factor … from the region’s drug evaluation committee the …
-
Vasomotor Symptoms Market is Likely to Increase at a Steady Growth Rate by 2034, Estimated DelveInsight | Key Companies - Estetra, Bayer, Hansoh BioMedical R&D Company, Mitsubishi Tanabe Pharma, Astellas Pharma Inc
28 Feb 2024 18:00 GMT
… Analysis of Emerging Vasomotor Symptoms Drugs
Competitive Intelligence Analysis: SWOT analysis … , QUE Oncology, Bayer, Endoceutics, Astellas Pharma, Mitsubishi Tanabe Pharma, MenoGenix, among others. Menopause Market …
-
Pharmaceutical and Biotechnology Royalty Rates Report and Directory 2024: Technology Licensed, License Fees, Upfront and Milestone Payments for Deals Signed Since 2020 - ResearchAndMarkets.com
13 Mar 2024 13:11 GMT
…
Drugs for Neglected Diseases Initiative
DS Healthcare
Duke University
Dyax
Eagle Pharmaceuticals … Therapeutics
Miraculins
Miralogx
Mira Pharmaceuticals
Miromatrix Medical
Mitsubishi Tanabe Pharma
Moderna
Modis Therapeutics
Moleculin …
-
Amylyx plummets as confirmatory trial of ALS drug fails
11 Mar 2024 10:41 GMT
… and debates around the drug’s efficacy, becoming only … drug for ALS ever to be approved in the US after Mitsubishi Tanabe … ’s Radicava (edaravone) and generic drug riluzole, … to accelerated approval of drugs with limited efficacy data. …